Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-504 and Docetaxel in Previously Treated NSCLC
NCT01362400Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- May 2011
- Primary completion
- Mar 2014
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing IPI-504 + Docetaxel with Placebo + Docetaxel (2 arms). Primary endpoint: Overall Survival at 3 years. Started May 2011; status: completed.
02
Drugs
retaspimycin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01362400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362400.